TapewireFind a company

person · Reporting owner

BENDHEIM JACK

Disclosed activity across 1 company

Tapewire entity
25172
SEC CIK
0001241560

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
PHIBRO ANIMAL HEALTH CORPPAHC · Entity 4671Director · Executive Chairman · 10% ownerAugust 06, 2026August 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

PHIBRO ANIMAL HEALTH CORP

Report date August 06, 2026 · Filed August 10, 2026

Jointly reported with BFI Co., LLC

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect26,640 Reported balance After 2026-08-06 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2026-08-06 · Grant · Acquired 12,103 · Balance 26,640

F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.

F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date.

F3: The reported securities are directly held by Jack Bendheim.

Class A Common StockSEC Table I · non-derivativeIndirectSee56,152 Reported balance Holding disclosure · report date 2026-08-06 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 56,152

F4: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.

F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date.

F3: The reported securities are directly held by Jack Bendheim.

F4: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 06, 2026 Filed Aug 10, 2026 20:16 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 GrantClass A Common Stock 12,103 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-093385 · tm2622592-3_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · Executive Chairman · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,640

F1 · security: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.

F2 · shares: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date.

F3 · ownership.direct: The reported securities are directly held by Jack Bendheim.

Read SEC document
August 04, 2026 Filed Aug 7, 2026 00:12 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 OtherClass A Common Stock 2,303 $36.60 $84,287.50
Disclosure

SEC source: 0001104659-26-092233 · tm2622506-6_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · Executive Chairman · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,537

F1 · shares: Represents shares sold in a broker assisted cashless exercise program to satisfy tax withholding obligations upon the receipt of Class A Common Stock in connection with the vesting and settlement of restricted stock units.

F2 · ownership.direct: The reported securities are directly held by Jack Bendheim.

Read SEC document
May 07, 2026 Filed May 7, 2026 23:34 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 2,029 $49.19 $99,815.03
Disclosure

SEC source: 0001104659-26-057389 · tm2613857-1_4seq1.xml · nonDerivative · entry 7

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 56,152

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.50.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
May 07, 2026 Filed May 7, 2026 23:34 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 1,149 $48.31 $55,505.20
Disclosure

SEC source: 0001104659-26-057389 · tm2613857-1_4seq1.xml · nonDerivative · entry 6

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 58,181

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.835.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
May 07, 2026 Filed May 7, 2026 23:34 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 1,350 $47.59 $64,247.58
Disclosure

SEC source: 0001104659-26-057389 · tm2613857-1_4seq1.xml · nonDerivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 59,330

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.995.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
May 06, 2026 Filed May 7, 2026 23:34 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 1,406 $58.13 $81,724.73
Disclosure

SEC source: 0001104659-26-057389 · tm2613857-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 60,680

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.965 to $58.31.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
May 06, 2026 Filed May 7, 2026 23:34 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 5,634 $57.18 $322,125.08
Disclosure

SEC source: 0001104659-26-057389 · tm2613857-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 62,086

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.825 to $57.72.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
May 05, 2026 Filed May 7, 2026 23:34 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 776 $56.37 $43,739.24
Disclosure

SEC source: 0001104659-26-057389 · tm2613857-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 67,720

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.235 to $56.51.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
May 05, 2026 Filed May 7, 2026 23:34 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 6,264 $55.73 $349,070.80
Disclosure

SEC source: 0001104659-26-057389 · tm2613857-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 68,496

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.225 to $56.21. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 through 9.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 30, 2026 Filed Apr 30, 2026 23:20 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 1,235 $53.32 $65,847.61
Disclosure

SEC source: 0001104659-26-053249 · tm2613153-1_4seq1.xml · nonDerivative · entry 7

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 74,760

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.22 to $53.39.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 30, 2026 Filed Apr 30, 2026 23:20 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 5,805 $52.65 $305,617.58
Disclosure

SEC source: 0001104659-26-053249 · tm2613153-1_4seq1.xml · nonDerivative · entry 6

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 75,995

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.16 to $53.09.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 29, 2026 Filed Apr 30, 2026 23:20 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 3,038 $53.21 $161,645.30
Disclosure

SEC source: 0001104659-26-053249 · tm2613153-1_4seq1.xml · nonDerivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 81,800

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.775.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 29, 2026 Filed Apr 30, 2026 23:20 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 4,002 $52.70 $210,907.40
Disclosure

SEC source: 0001104659-26-053249 · tm2613153-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 84,838

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.97.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 28, 2026 Filed Apr 30, 2026 23:20 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 797 $56.69 $45,181.61
Disclosure

SEC source: 0001104659-26-053249 · tm2613153-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 88,840

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.53 to $56.875.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 28, 2026 Filed Apr 30, 2026 23:20 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 4,591 $56.06 $257,374.67
Disclosure

SEC source: 0001104659-26-053249 · tm2613153-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 89,637

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.51 to $56.50.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 28, 2026 Filed Apr 30, 2026 23:20 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 1,652 $55.10 $91,018.59
Disclosure

SEC source: 0001104659-26-053249 · tm2613153-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 94,228

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.51 to $55.40. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 through 9.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 23, 2026 Filed Apr 23, 2026 23:30 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 421 $54.56 $22,969.00
Disclosure

SEC source: 0001104659-26-047933 · tm2612536-1_4seq1.xml · nonDerivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 95,880

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.515 to $54.61.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 23, 2026 Filed Apr 23, 2026 23:30 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 6,619 $54.07 $357,856.90
Disclosure

SEC source: 0001104659-26-047933 · tm2612536-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 96,301

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.51 to $54.50.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 22, 2026 Filed Apr 23, 2026 23:30 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 7,040 $54.29 $382,184.70
Disclosure

SEC source: 0001104659-26-047933 · tm2612536-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 102,920

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.73 to $54.665.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 21, 2026 Filed Apr 23, 2026 23:30 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 5,415 $56.17 $304,136.72
Disclosure

SEC source: 0001104659-26-047933 · tm2612536-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 109,960

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.91 to $56.56.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 21, 2026 Filed Apr 23, 2026 23:30 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 1,625 $55.35 $89,943.91
Disclosure

SEC source: 0001104659-26-047933 · tm2612536-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 115,375

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.905 to $55.88. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4, 5, 6 and 7.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 16, 2026 Filed Apr 17, 2026 00:25 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 ConversionClass B Common Stock · Derivative 100,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · derivative · entry 10

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 19,496,034

Underlying: Class A Common Stock · 100,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F8 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 16, 2026 Filed Apr 17, 2026 00:25 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 1,850 $54.88 $101,520.42
Disclosure

SEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · nonDerivative · entry 8

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 117,000

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F10 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.80 to $54.985.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 16, 2026 Filed Apr 17, 2026 00:25 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 5,190 $54.56 $283,141.49
Disclosure

SEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · nonDerivative · entry 7

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 118,850

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.80 to $54.79.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 16, 2026 Filed Apr 17, 2026 00:25 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 ConversionClass A Common Stock 100,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · nonDerivative · entry 6

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 124,040

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 15, 2026 Filed Apr 17, 2026 00:25 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 799 $58.11 $46,431.97
Disclosure

SEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · nonDerivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 24,040

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.92 to $58.22.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 15, 2026 Filed Apr 17, 2026 00:25 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 3,618 $57.21 $206,985.42
Disclosure

SEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 24,839

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.90 to $57.88.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 15, 2026 Filed Apr 17, 2026 00:25 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 2,623 $56.27 $147,593.85
Disclosure

SEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 28,457

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.87 to $56.73.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 14, 2026 Filed Apr 17, 2026 00:25 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 492 $59.69 $29,368.66
Disclosure

SEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 31,080

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.63 to $59.83.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 14, 2026 Filed Apr 17, 2026 00:25 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 6,548 $59.03 $386,553.32
Disclosure

SEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 31,572

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.63 to $59.61. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4, 5, 6, 7, 9 and 10.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 31, 2026 Filed Mar 31, 2026 22:44 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 431 $54.35 $23,426.27
Disclosure

SEC source: 0001104659-26-037978 · tm2610803-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 38,120

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.28 to $54.51.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 31, 2026 Filed Mar 31, 2026 22:44 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 6,609 $53.87 $356,001.72
Disclosure

SEC source: 0001104659-26-037978 · tm2610803-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 38,551

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.27 to $54.26.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 30, 2026 Filed Mar 31, 2026 22:44 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 617 $54.31 $33,508.65
Disclosure

SEC source: 0001104659-26-037978 · tm2610803-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 45,160

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.23 to $54.385.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 30, 2026 Filed Mar 31, 2026 22:44 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 6,423 $53.54 $343,897.05
Disclosure

SEC source: 0001104659-26-037978 · tm2610803-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 45,777

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.23 to $54.075. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4, 5 and 6.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 26, 2026 Filed Mar 27, 2026 01:19 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 280 $57.17 $16,007.66
Disclosure

SEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 7

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 52,200

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.14 to $57.24.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 26, 2026 Filed Mar 27, 2026 01:19 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 6,760 $56.79 $383,867.95
Disclosure

SEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 6

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 52,480

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.12 to $57.06.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 25, 2026 Filed Mar 27, 2026 01:19 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 552 $56.86 $31,385.84
Disclosure

SEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 59,240

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.76 to $56.91.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 25, 2026 Filed Mar 27, 2026 01:19 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 4,916 $56.00 $275,316.16
Disclosure

SEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 59,792

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.76 to $56.745.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 25, 2026 Filed Mar 27, 2026 01:19 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 1,572 $55.28 $86,903.62
Disclosure

SEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 64,708

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.69 to $55.65.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 24, 2026 Filed Mar 27, 2026 01:19 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 517 $53.59 $27,705.31
Disclosure

SEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 66,280

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.53 to $53.70.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 24, 2026 Filed Mar 27, 2026 01:19 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 6,523 $52.88 $344,917.98
Disclosure

SEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 66,797

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.44 to $53.435. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 through 9.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 19, 2026 Filed Mar 19, 2026 23:58 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 124 $53.24 $6,601.76
Disclosure

SEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 7

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 73,320

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 19, 2026 Filed Mar 19, 2026 23:58 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 4,977 $52.79 $262,717.91
Disclosure

SEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 6

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 73,444

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.195 to $53.125.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 19, 2026 Filed Mar 19, 2026 23:58 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 1,939 $51.78 $100,409.37
Disclosure

SEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 78,421

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.19 to $52.18.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 18, 2026 Filed Mar 19, 2026 23:58 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 2,651 $53.64 $142,209.18
Disclosure

SEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 80,360

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.365 to $53.88.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 18, 2026 Filed Mar 19, 2026 23:58 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 3,598 $53.03 $190,819.21
Disclosure

SEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 83,011

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.35 to $53.295.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 18, 2026 Filed Mar 19, 2026 23:58 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 4,311 $51.80 $223,301.18
Disclosure

SEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 86,609

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.29 to $52.21.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 17, 2026 Filed Mar 19, 2026 23:58 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 5,280 $51.66 $272,759.52
Disclosure

SEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 90,920

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.26 to $52.13. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 through 8.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 13, 2026 Filed Mar 16, 2026 20:15 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 SaleClass A Common Stock 5,280 $48.91 $258,244.80
Disclosure

SEC source: 0001104659-26-028472 · tm268840-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 96,200

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on December 11, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.48 to $49.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
March 12, 2026 Filed Mar 16, 2026 20:15 UTC PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 ConversionClass B Common Stock · Derivative 100,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001104659-26-028472 · tm268840-1_4seq1.xml · derivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 19,596,034

Underlying: Class A Common Stock · 100,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.